Bausch + Lomb Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bausch + Lomb Inc.
A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Switch consultant Susan Levy suggests drug firms temper enthusiasm for Rx-to-OTC switches with considering the costs NDAs generate and the histories of switches that haven’t been successes.
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
- Other Names / Subsidiaries
- Bausch & Lomb
- Bausch + Lomb Technolas
- ISTA Pharmaceuticals, Inc. (ISTA)
- Laboratorio Pförtner Cornealent SACIF, Waicon
- Technolas Perfect Vision GmbH